Baraclude

DRUG3 trials

Sponsors

Hanmi Pharmaceutical Company Limited, Bristol-Myers Squibb, Shanghai Zhimeng Biopharma, Inc.

Conditions

Chronic Hepatitis BHepatitis B VirusHepatitis B, Chronic

Phase 1

A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting

CompletedNCT03083821

Bristol-Myers SquibbHepatitis B Virus

Start: 2017-05-16End: 2017-12-19Updated: 2023-11-18

Phase 2

A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB

Shanghai Zhimeng Biopharma, Inc.Hepatitis B, Chronic

Start: 2022-11-11End: 2024-12-30Target: 90Updated: 2023-05-08

Phase 4

Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude

Hanmi Pharmaceutical Company LimitedChronic Hepatitis B

Start: 2015-01-31End: 2017-02-28Target: 134Updated: 2015-08-14